+ Filter
Loading...
E2
Anti-E2 Recombinant Antibody Products
- Recombinant Human Anti-VEEV E2 Antibody (F5) (PABL-357)
-
- Derivation: Human
- Species Reactivity: VEEV
- Type: IgG
- Application: WB, ELISA, Neut, FuncS
Compare
- Recombinant Rat Anti-HCV E2 Antibody (3/11) (PABL-118)
-
- Derivation: Rat
- Species Reactivity: HCV
- Type: IgG
- Application: WB, ELISA, Neut, FuncS
Compare
- Human Anti-E2 Recombinant Antibody (clone D12) (HPAB-2105-FY)
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA
Compare
- Mouse Anti-E2 Antibody (clone mAb#8), mRNA (PABZ-180-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone mAb 12), mRNA (PABL-465-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone F5), mRNA (PABL-357-mRNA)
-
- Species Reactivity: VEEV
Compare
- Human Anti-E2 Antibody (PABL-124-mRNA), mRNA (PABL-124-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone mAb8), mRNA (PABL-123-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone mAb12), mRNA (PABL-122-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone TRN-1007), mRNA (HPAB-N0075-YC-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone TRN-1008), mRNA (HPAB-N0074-YC-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone HC84.26.5D), mRNA (HPAB-N0072-YC-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone hu5B3.v3), mRNA (PABZ-181-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone HC84-27), mRNA (PABL-121-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone HC84-1), mRNA (PABL-120-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone HC33.1), mRNA (PABL-119-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone mAb1:7), mRNA (PABC-184-mRNA)
-
- Species Reactivity: HCV
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: BV421
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: FITC
Compare
- DRB1*03:01/HPV E2 (PIVQLQGDSNCLKCFR) MHC Monomer (MHC-YF094)
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: PIVQLQGDSNCLKCFR
- Conjugate: Biotin
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: PE
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: APC
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: Biotin
Compare
- Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47W) (TAB-239CT-F(E))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47F) (TAB-238CT-F(E))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47W) (TAB-239CT-S(P))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47F) (TAB-238CT-S(P))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody (Y47W) (TAB-239CT)
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody (Y47F) (TAB-238CT)
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Human Anti-HCV E2 Recombinant Antibody (AP33) (TAB-020CT)
-
- Derivation: Phage display library
- Species Reactivity: genotypes 1-6 of HCV
- Type: Human antibody
- Application: ELISA, IP, Neut, FC, WB
Compare
- Recombinant Human Anti-E2 Antibody (TRN-1007) (HPAB-N0075-YC)
-
- Species Reactivity: HCV
- Type: Human IgG
- Application: Neut, ELISA, WB
Compare
- Recombinant Humanized Anti-E2 Antibody (TRN-1008) (HPAB-N0074-YC)
-
- Derivation: Humanized
- Species Reactivity: HCV
- Type: Humanized IgG
- Application: Neut, ELISA, WB
Compare
- Recombinant Human Anti-E2 Antibody (HC84.26.5D) (HPAB-N0072-YC)
-
- Species Reactivity: HCV
- Type: Human IgG
- Application: Neut, ELISA, FuncS
Compare
- Recombinant Human Anti-E2 Antibody scFv Fragment (HC84.26.5D) (HPAB-N0072-YC-S(P))
-
- Species Reactivity: HCV
- Type: Human scFv
- Application: Neut, ELISA, FuncS
Compare
- Human Anti-E2 Recombinant Antibody (clone D12); scFv Fragment (HPAB-2105-FY-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA
Compare
- Recombinant Human Anti-E2 Antibody scFv Fragment (TRN-1007) (HPAB-N0075-YC-S(P))
-
- Species Reactivity: HCV
- Type: Human scFv
- Application: Neut, ELISA, WB
Compare
- Recombinant Humanized Anti-E2 Antibody scFv Fragment (TRN-1008) (HPAB-N0074-YC-S(P))
-
- Derivation: Humanized
- Species Reactivity: HCV
- Type: Humanized scFv
- Application: Neut, ELISA, WB
Compare
- Recombinant Human Anti-E2 Antibody Fab Fragment (TRN-1007) (HPAB-N0075-YC-F(E))
-
- Species Reactivity: HCV
- Type: Human Fab
- Application: Neut, ELISA, WB
Compare
- Recombinant Humanized Anti-E2 Antibody Fab Fragment (TRN-1008) (HPAB-N0074-YC-F(E))
-
- Derivation: Humanized
- Species Reactivity: HCV
- Type: Humanized Fab
- Application: Neut, ELISA, WB
Compare
- Recombinant Human Anti-E2 Antibody Fab Fragment (HC84.26.5D) (HPAB-N0072-YC-F(E))
-
- Species Reactivity: HCV
- Type: Human Fab
- Application: Neut, ELISA, FuncS
Compare
- Human Anti-E2 Recombinant Antibody (clone D12); Fab Fragment (HPAB-2105-FY-F(E))
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA
Compare
More Infomation
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Advances in treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) have led to high cure rates of treated patients. Although rates of sustained virologic response of approximately 95% have been achieved, a large number of patients still fail treatment, even with drug combination regiments. A high percentage of these treatment failures are due to the emergence of resistance-associated variants (RAV). Chronic HCV infection consequently will continue as a leading cause of cirrhosis and hepatocellular carcinoma, which are major indications for liver transplantation.
